Dentsply Sirona's turnaround story has a credibility problem that has nothing to do with its tone. Last quarter management sounded more assured than it had in a while. It pointed to a packed implant summit, a fully recertified US implant sales force, European dental service organizations adopting DS Core, and the first share buyback since 2024. Since then, investors have sent the stock down about 29%, while the S&P 500 was essentially flat. When the company reports third-quarter results after the close on November 5, it needs to show that the Return to Growth plan is producing numbers, not just anecdotes.

The bar is deliberately low. Consensus calls for earnings of $0.30 per share on revenue of $856 million. That would be a decline of about 19% in profit and roughly 5% in sales from a year ago. It also marks a clear step down from the second quarter's $0.52 and $898 million. The sequential drop is not a surprise. Management told investors to expect lower revenue on seasonality and lower earnings once the one-time $44 million tariff refund drops out. That refund added about 17 cents to second-quarter EPS, so the underlying comparison is closer to the mid-30s. Matching expectations would confirm the company's forecasting discipline, but it would not prove a recovery.

The more revealing tension sits in the full-year math. Management has held its 2026 outlook steady for three straight quarters: adjusted EPS of $1.40 to $1.50 and revenue of $3.5 billion to $3.6 billion. The Street sits at $1.42 and $3.58 billion. Earnings forecasts are hugging the bottom of the range, while revenue forecasts lean toward the top. First-half sales totaled about $1.78 billion. If the third quarter lands near $856 million, the fourth quarter would need to deliver roughly $946 million to hit consensus. That would be the strongest quarter of the year by a wide margin. Any trim to the revenue range, or any hint that the fourth-quarter inflection is slipping into 2027, would challenge the core of the turnaround narrative.

Several operating threads will show which way that goes. Orthodontic and implant solutions was the weakest segment last quarter, down about 6% even excluding Byte, with SureSmile still falling by double digits in the Americas. Investors should look for evidence that the retrained implant force is translating into orders. On the equipment side, management flagged a new risk: European dentists deferring capital purchases amid the Middle East conflict, while Americas equipment sales fell about 10%. European distributor destocking was showing sequential improvement and should be closer to finished. Fresh weakness there would be hard to explain away. The bright spots that need to hold are WellSpect, which accelerated to 7% growth, and double-digit milling growth in Asia-Pacific. Margins also matter. Management said it has been absorbing higher freight and input costs and may stop doing so, so any pricing action or margin slippage is worth noting.

Sentiment has edged slightly more bearish than before the last report, and the stock tells a starker story. At $9.44 it trades well below its 200-day moving average of $11.36. It sits near the bottom of its post-earnings range of $8.32 to $13.58, below the sub-$10 level where the company bought back shares. Whether management keeps repurchasing at these prices, and how the new CFO frames cash deployment, will signal how much confidence the leadership truly has.

In the end, this report comes down to whether the fourth-quarter ramp still looks achievable. Reaffirmed guidance backed by stabilizing implants and orthodontics, plus contained European equipment weakness, would keep the turnaround intact and could leave a beaten-down stock room to recover. Another quarter of contraction without a credible bridge to that back-half step-up would suggest the 24-month plan is running behind its own timetable.